Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • COVAX

    - PMLiVE

    Moderna’s LP.8.1-adapted COVID-19 vaccine recommended by CHMP

    Global health authorities have recommended that vaccines for the 2025-2026 season should target LP.8.1

    - PMLiVE

    Moderna shares positive phase 3 results for mRNA flu vaccine candidate

    More than 600,000 people in the US were hospitalised due to flu-related illness last year

    - PMLiVE

    Moderna’s RSV vaccine mRESVIA granted FDA approval to protect younger adults

    The vaccine is already approved in the US for use in adults aged 60 years and older

    - PMLiVE

    Moderna’s RSV vaccine mRESVIA granted MHRA approval to protect older adults

    RSV is responsible for 14,000 hospitalisations per year in UK adults aged 65 years and older

    - PMLiVE

    Moderna’s JN.1-adapted COVID-19 vaccine approved by MHRA for adults and children

    The JCVI has already advised the UK government on eligible groups for this year’s autumn vaccination programme

    - PMLiVE

    Novavax’s JN.1-adapted COVID-19 vaccine granted FDA emergency use authorisation

    JN.1 only accounts for 0.2% of cases across the country but is the ‘parent strain’ of currently circulating variants

    - PMLiVE

    FDA approves updated COVID-19 vaccines to better protect against current variants

    Adapted vaccines from Pfizer/BioNTech and Moderna have been authorised for individuals aged six months and older

    - PMLiVE

    JCVI announces advice for autumn COVID-19 vaccination programme eligibility

    The Committee has advised offering the vaccine to those at high risk of serious disease

    - PMLiVE

    Moderna shares positive late-stage results for COVID-19/flu combination vaccine

    The combined vaccine approach could simplify immunisation practices and lead to higher uptake

    - PMLiVE

    Moderna/Merck share positive three-year results for investigational skin cancer vaccine

    More than 100,000 new cases of melanoma are expected to be diagnosed in the US in 2024

    - PMLiVE

    Moderna’s RSV vaccine mRESVIA granted FDA approval for use in older adults

    The approval marks the first time an mRNA vaccine has been approved for a disease other than COVID-19

    - PMLiVE

    AstraZeneca’s sipavibart shown to prevent COVID-19 in immunocompromised patients

    Immunocompromised individuals account for about 25% of COVID-19 hospitalisations, intensive care unit admissions and deaths

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links